Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2026Dermatology and TherapyOpen Access

AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMatthias AugustinAPAndreas PinterSSSilvia Sabatino

Discussion

Loading...

Member takes

Overview

Observational cohort study finds lower discontinuation rates for baricitinib in adults with atopic dermatitis, indicating improved effectiveness.

Key Points

  • This research aims to assess the discontinuation rates and treatment responses of oral systemics for moderate-to-severe atopic dermatitis.
  • Multinational observational cohort study involving adult patients with moderate-to-severe AD.
  • Patients commenced either conventional systemics or baricitinib over a 12-month period.
  • Primary objective assessed discontinuation rates at week 24.
  • At week 24, treatment discontinuation was 50.8% for conventional systemics, 29.0% for baricitinib, and 18.8% for other Janus kinase inhibitors.
  • Patients on baricitinib and other JAKis had higher improvement rates in eczema area and severity index and pain compared to conventional systemics.
  • 81.0% of baricitinib patients achieved an EASI ≤ 7, indicating significant clinical improvement.

Cite This Study

Augustin et al. (2026) studied this question.

synapsesocial.com/papers/6a6eeaa21b0468a7eeab2ec8https://doi.org/10.1007/s13555-026-01852-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P097 ‘Real-world’ Janus kinase inhibitor treatments in the UK-Irish A-STAR register: cohort profile and treatment outcomes2024
  2. 2Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four <scp>JAK</scp> Inhibitors in Moderate‐To‐Severe Atopic Dermatitis2026 · 1 citations
  3. 3Baricitinib for Itch-Dominant Atopic Dermatitis: A 52 Weeks Baricitinib Real-World Experience in Korea2026
  4. 4Real-world effectiveness and safety of baricitinib including its effect on biomarkers and laboratory data in Japanese adult patients with atopic dermatitis: a single-center retrospective study2024 · 9 citations
  5. 5Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study2026